Abstract: The present invention relates to pharmaceutical compositions and methods for the treatment of viral respiratory infections. More specifically, the present invention relates to IL-18 antagonists and their use in the treatment of a viral respiratory infection in a subject having: (a) a deficiency of IL-18 binding protein; and/or (b) a deficiency of natural killer cells and/or a deficiency of functional natural killer cells.